Clinical Trials Browser

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

Neoplasms, Neuroblastoma

Neuroblastoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasm Metastasis, Sarcoma

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Carcinoma, Carcinoma, Pancreatic Ductal

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

ALK-positive NSCLC

ALK-positive Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lymphoma, B-Cell, Hematologic Neoplasms

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Carcinoma, Non-Small-Cell Lung

ALK-positive Advanced Tumors

Carcinoma, Non-Small-Cell Lung, Neoplasms

Adenocarcinoma of Lung

Brain Neoplasms, Glioblastoma

Carcinoma, Non-Small-Cell Lung

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Carcinoma, Non-Small-Cell Lung

Noonan Syndrome 6, Melanoma

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Lymphoma, Large-Cell, Anaplastic

Thyroid Carcinoma, Anaplastic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Cholangiocarcinoma

Adenocarcinoma Of Esophagus, Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung

Hematologic Neoplasms

Clinical Trials

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Managed Access Programs for LDK378, Ceritinib

NEPENTHE

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

PEDS-PLAN

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

MULTISARC

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

DELINOR

Using Tumor Models to Determine Treatments

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

IMPRESS-N

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Antineoplastic Drugs in Elderly Patients

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

SIGNATURE

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Ascend-7

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Ceritinib Rare Indications Study in ALK+ Tumors

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies